Allogene Therapeutics (ALLO) Change in Accured Expenses (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Change in Accured Expenses data on file, last reported at -$5.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 2.34% year-over-year to -$5.1 million; the trailing twelve-month figure through Mar 2026 stood at -$2.4 million (down 201.64% YoY), and the FY2025 full-year result was -$2.5 million, down 99.68% from the prior year.
• Change in Accured Expenses eased to -$5.1 million in Q1 2026, from -$118000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.7 million in Q2 2022 to a low of -$12.7 million in Q3 2023.
• A 5-year average of -$821000.0 and a median of $286000.0 in 2023 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 906.99% in 2024, while the deepest fall reached 1140.51% in 2024.
• Tracing ALLO's Change in Accured Expenses over 5 years: stood at $3.1 million in 2022, then plunged by 90.88% to $286000.0 in 2023, then jumped by 906.99% to $2.9 million in 2024, then tumbled by 104.1% to -$118000.0 in 2025, then slumped by 4222.88% to -$5.1 million in 2026.
• Business Quant data shows ALLO's Change in Accured Expenses at -$5.1 million in Q1 2026, -$118000.0 in Q4 2025, and $1.1 million in Q3 2025.